Inhibrx Inc INBX:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 1:14 PM EDT
34.07quote price arrow down-0.22 (-0.64%)
Volume
685,432
52 week range
14.31 - 39.79
Loading...
  • Open34.31
  • Day High34.43
  • Day Low33.95
  • Prev Close34.29
  • 52 Week High39.79
  • 52 Week High Date02/27/24
  • 52 Week Low14.31
  • 52 Week Low Date10/31/23

Key Stats

  • Market Cap1.781B
  • Shares Out52.28M
  • 10 Day Average Volume0.41M
  • Dividend-
  • Dividend Yield-
  • Beta2.85
  • YTD % Change-10.34

KEY STATS

  • Open34.31
  • Day High34.43
  • Day Low33.95
  • Prev Close34.29
  • 52 Week High39.79
  • 52 Week High Date02/27/24
  • 52 Week Low14.31
  • 52 Week Low Date10/31/23
  • Market Cap1.781B
  • Shares Out52.28M
  • 10 Day Average Volume0.41M
  • Dividend-
  • Dividend Yield-
  • Beta2.85
  • YTD % Change-10.34

RATIOS/PROFITABILITY

  • EPS (TTM)-5.35
  • P/E (TTM)-6.37
  • Fwd P/E (NTM)-8.26
  • EBITDA (TTM)-248.023M
  • ROE (TTM)-2,031.05%
  • Revenue (TTM)1.783M
  • Gross Margin (TTM)-
  • Net Margin (TTM)-15,116.15%
  • Debt To Equity (MRQ)1,799.88%

EVENTS

  • Earnings Date08/05/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Inhibrx Inc

 

Profile

MORE
Inhibrx, Inc. is a clinical-stage biopharmaceutical company, which is focused on developing a broad pipeline of novel biologic therapeutic candidates. The Company’s pipeline is focused on oncology and orphan diseases. Its clinical pipeline includes therapeutic candidates, such as INBRX-101, and INBRX-109. INBRX-101 is an engineered recombinant human alpha-1 antitrypsin fragment crystallizable (AAT-Fc) fusion protein therapeutic candidate that the Company is developing for the...
Mark Lappe
Chairman of the Board of Director, President, Chief Executive Officer, Co-Founder
Kelly Deck CPA
Chief Financial Officer
Address
11025 N. Torrey Pines Road, Suite 200
La Jolla, CA
92037
United States

Top Peers

SYMBOLLASTCHG%CHG
FUSN
Fusion Pharmaceuticals Inc
21.43-0.05-0.23%
EWTX
Edgewise Therapeutics Inc
17.92-0.41-2.24%
SNDX
Syndax Pharmaceuticals Inc
21.19-0.56-2.57%
VERA
Vera Therapeutics Inc
40.02-1.30-3.16%
KURA
Kura Oncology Inc
20.40-0.31-1.50%